Drug intelligence / Profile preview

DDD-024

Development stage: Preclinical
Lead developer: Daya CNS
Modality: Small Molecules

Overview

DDD-024 is a preclinical-stage small molecule drug being developed by Daya CNS for the treatment of substance use disorders, specifically targeting methamphetamine, amphetamine, and opioid addiction. The compound is part of a proprietary non-opioid pyridoindole platform invented by Dr. Parthasarathi Rajagopalan. DDD-024 has demonstrated efficacy in preclinical rat models of methamphetamine self-administration, showing potential to reduce drug-seeking behavior without the adverse effects or abuse potential associated with opioid-based therapies. As of early 2024, the drug is in the pre-IND stage of development.

Beyond the preview

Go deeper on DDD-024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DDD-024.

Explore the full profile